Schneider Lab

Enjoy some of our most recent team photos taken at the precision genomics clinic!

Dr. Schneider presents our group's work, which was recently incorporated into the cancer guidelines (nccn.org), at the NCCN congress at Northwestern University in Chicago.

https://news.iu.edu/live/news/37840-iu-research-targets-debilitating-side-effects-for

IU research targets debilitating side effects for Black breast cancer patients IU researchers are leading the way to improving quality of life and curative chemotherapy doses for Black patients with breast cancer — with help from t...

"The results of this study are concordant with other in vitro drug toxicity studies highlighting similar significant experimental parameters affecting dose response. However, our study specifically examines these parameters in the context of an iPSC-derived sensory neuron model, identifying optimal conditions for the evaluation of taxane-induced neurotoxicity." (Cantor et al., 2024)

Read more here: https://rdcu.be/dRbKn

Check out our latest work, just published with Springer Nature in Scientific Reports, concerning the optimization of our neuron model for the assessment of taxane-induced neurotoxicity. You can access the article for free here: https://rdcu.be/dRbKn

https://ascopubs.org/do/eaz171-predictors-tipn-black-women-breast-cancer

EAZ171: Predictors of TIPN in Black Women with Breast Cancer | ASCO Publications Dr. Shannon Westin and her guest, Dr. Bryan Schneider discuss the article “ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-induced Peripheral Neuropathy in Black Women with Early Stage Breast Cancer” recently published in the JCO and presented at the 2024 ASCO An...

https://ascopost.com/news/june-2024/study-including-only-black-patients-with-breast-cancer-compares-rates-of-taxane-induced-peripheral-neuropathy/

Study Including Only Black Patients With Breast Cancer Compares Rates of Taxane-Induced Peripheral Neuropathy New findings suggest that docetaxel may be considered the preferred treatment over paclitaxel for Black patients with early-stage breast cancer. While the EAZ171 trial focused specifically on Black pe...

https://www.komen.org/blog/personalized-chemo/

Personalizing Chemotherapy for Black Women - Susan G. Komen® Komen Scholar Bryan Schneider, M.D., trial lead for the EAZ171 clinical trial, is seeking to overcome these disparities in outcomes for Black women with breast cancer by personalizing chemotherapy.

https://medicine.iu.edu/news/2024/06/eaz171-breast-cancer-study

Chemotherapy type can be personalized to decrease harmful side effects for Black patients with breast cancer New study by IU cancer center researchers could improve quality of life and curative chemotherapy doses for Black patients who face disparate outcomes in breast cancer

Exciting news from the world of science!

Tarah Ballinger, MD, a dedicated researcher at IU School of Medicine, is making strides in breast cancer research. Notably, Dr. Ballinger has previously utilized KTB samples to delve into the intricacies of breast cancer.

Her recent work on the EAZ171 clinical trial is a testament to her commitment to advancing the field. Click the link to read about how Chemotherapy type can be personalized to decrease harmful side effects for Black patients with breast cancer: https://medicine.iu.edu/news/2024/06/eaz171-breast-cancer-study

Stay tuned for more updates as we continue to support and celebrate the incredible contributions of researchers like Dr. Ballinger in the fight against breast cancer.